Lenvatinib: tested in a combination
307 studies: another drug in the study is under test too. Page 2 of 4. Open to participants first (149), then studies with results posted, then the rest; newest registration first within each.
- The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breast Cancer: a Phase Ib/IIa Clinical Trial.Not yet recruitingNCT06140576Phase 1/2Report a problem
- Pucotenlimab Combined With Lenvatinib as a Neodjuvant Therapy for Non Clear Cell Renal Cell CarcinomaNot yet recruitingNCT06129955Phase 2Report a problem
- A Study to Evaluate Sintilimab Plus Lenvatinib as Adjuvant Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis (PVTT) After Surgical ResectionNot yet recruitingNCT06089382Phase 3Report a problem
- bTAE-HAIC Combined With Lenvatinib and Sintilimab for Infiltrative Hepatocellular CarcinomaRecruitingNCT06070636Not applicableReport a problem
- bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCCRecruitingNCT06061276Not applicableReport a problem
- Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver TransplantationNot yet recruitingNCT06041490Phase 2Report a problem
- Cryoablation Combined with Tislelizumab Plus Lenvatinib in Previously Treated Solid Tumors (CASTLE-11)RecruitingNCT06032845Phase 2Report a problem
- Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC PatientsNot yet recruitingNCT06028633Phase 2Report a problem
- A Clinical Study of Tislelizumab Combined With TACE and Lenvatinib in the Neoadjuvant Treatment of Resectable HCCRecruitingNCT06003673Phase 4Report a problem
- Lenvatinib, Sintilimab Plus SIRT for Unresectable HCCRecruitingNCT05992584Phase 2Report a problem
- Lenvatinib, Tislelizumab Combined With RALOX Regimen HAIC in Advanced Hepatocellular CarcinomaRecruitingNCT05954897Phase 2Report a problem
- OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older AdultsNot yet recruitingNCT05949424Phase 4Report a problem
- Durvalumab and Lenvatinib With or Without Chemotherapy in First-Line Treatment of Advanced Biliary Tract CancerRecruitingNCT05935579Phase 2Report a problem
- Lenvatinib Combined with Tislelizumab and TACE Applied As Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma with High-risk Recurrence FactorsRecruitingNCT05920863Phase 2Report a problem
- Adjuvant Tislelizumab Plus Lenvatinib for Patients at High-risk of HCC Recurrence After Curative Resection or AblationNot yet recruitingNCT05910970Phase 3Report a problem
- Pembrolizumab Combination With Lenvatinib in Pts With Recurrent,Persistent,Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surgery or RadiotherapyRecruitingNCT05903833Phase 2Report a problem
- Cryoablation Combined With Tislelizumab Plus Lenvatinib in 1L Treatment of Advanced HCC (CASTLE-10)RecruitingNCT05897268Phase 2Report a problem
- A Study to Evaluate Lenvatinib Plus Tislelizumab for Locally Advanced Unresectable or Metastatic Hepatocellular Carcinoma With Hepatitis B Virus Infection and Biomarker AnalysesNot yet recruitingNCT05897138Phase 2Report a problem
- Cryoablation Combined With Tislelizumab Plus Lenvatinib In Previously Treated Gastric Cancer Liver Metastasis (CASTLE-09)RecruitingNCT05893056Phase 2Report a problem
- Cryoablation Combined With Sintilimab Plus Lenvatinib in 1L Treatment of Advanced ICC (CASTLE-ICC-Chemo-free)RecruitingNCT05835245Phase 2Report a problem
- First-line CBDCA/PTX/LEN/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas (Artemis)RecruitingNCT05832827Phase 2Report a problem
- Ablation in Combination With Lenvatinib and Anti-PD-1 AntibodiesRecruitingNCT05803928Phase 1Report a problem
- Cryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Biliary Tract Cancer (CASTLE-08)RecruitingNCT05781074Phase 2Report a problem
- Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine TumorsRecruitingNCT05746208Phase 2Report a problem
- Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell CarcinomaRecruitingNCT05733715Early Phase 1Report a problem
- Envafolimab, Lenvatinib Combined With TACE in the Treatment of Unresectable Locally Advanced Hepatocellular CarcinomaNot yet recruitingNCT05582109Phase 2Report a problem
- Sintilimab Combined With Lenvatinib Versus HAIC for Perioperative Treatment of Resectable Primary Hepatocellular CarcinomaRecruitingNCT05519410Phase 2Report a problem
- Tislelizumab Plus Lenvatinib in Stage III-IV RCCRecruitingNCT05485883Phase 2Report a problem
- Envofolimab and Lenvatinib Combined With Gemcitabine Plus Cisplatin for Advanced BTC as First-Line Treatment(ENLIGHTEN)RecruitingNCT05410197Phase 2Report a problem
- Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III StudyRecruitingNCT05342194Phase 3Report a problem
- Neoadjuvant Lenvatinib and Pembrolizumab for IVC Tumor ThrombusRecruitingNCT05319015Phase 2Report a problem
- Phase Ib/II Trial of Combining Pembrolizumab and Lenvatinib With SBRT for HCC Patients With Portal Vein Thrombosis.Not yet recruitingNCT05286320Phase 1/2Report a problem
- TACE/HAIC Combined With Lenvatinib and Sintilimab in Neoadjuvant Therapy for Intermediate-stage HCCRecruitingNCT05250843Phase 2/3Report a problem
- Safety and Efficacy of Lenvatinib and Anti-PD1 Antibody Combined With Radiotherapy Neoadjuvant Treatment for Resectable Hepatocellular Carcinoma With PVTTRecruitingNCT05225116Phase 1Report a problem
- Perioperative Pembrolizumab and Lenvatinib in Resectable Hepatocellular Carcinoma (HCC)RecruitingNCT05185739Phase 2Report a problem
- Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast Cancer, Post Progression on Al + CDK4/6 InhibitorRecruitingNCT05181033Phase 2Report a problem
- Radiofrequency Ablation Combined With Toripalimab and Lenvatinib in the Treatment of Short-term Recurrent Hepatocellular Carcinoma.Not yet recruitingNCT05162898Not applicableReport a problem
- Cryoablation Combined with Sintilimab Plus Lenvatinib in Previously Treated Unresectable Liver Metastasis from Solid TumorsRecruitingNCT05098847Phase 2Report a problem
- Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain MetastasesRecruitingNCT05064280Phase 2Report a problem
- Cryoablation Combined with Tislelizumab Plus Lenvatinib As Second-line or Later Therapy in Advanced Hepatocellular CarcinomaRecruitingNCT05057845Phase 2Report a problem
- Lenvatinib Plus Sintilimab in Patients with Immune Checkpoint Inhibitor Previously Treated Advanced Liver CancerRecruitingNCT05010681Phase 2Report a problem
- Pembrolizumab and Lenvatinib in Advanced Cervical CancerRecruitingNCT04865887Phase 2Report a problem
- Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid TumorsRecruitingNCT04803318Phase 2Report a problem
- Merck IIT: RRP Pembro and LenvatinibRecruitingNCT04645602Phase 2Report a problem
- Tislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable RHCCRecruitingNCT04615143Phase 2Report a problem
- Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian CancerRecruitingNCT04519151Phase 2Report a problem
- Durvalumab and Lenvatinib in Participants With Locally Advanced and Metastatic Hepatocellular Carcinoma ( Dulect2020-1 )RecruitingNCT04443322Not applicableReport a problem
- Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCCRecruitingNCT03899428Phase 2Report a problem
- The Drug Rediscovery Protocol (DRUP Trial)RecruitingNCT02925234Phase 2Report a problem
- Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve Metastatic Uveal MelanomaTerminatedNCT05308901Phase 2Results postedReport a problem
- Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial CancerTerminatedNCT05263492Phase 2Results postedReport a problem
- Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell CarcinomaTerminatedNCT04955743Phase 2Results postedReport a problem
- Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction CancerActive, not recruitingNCT04929392Phase 2Results postedReport a problem
- Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99)CompletedNCT04924101Phase 2Results postedReport a problem
- Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell CarcinomaActive, not recruitingNCT04869137Phase 2Results postedReport a problem
- Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) - China Extension StudyCompletedNCT04865289Phase 3Results postedReport a problem
- Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate CancerActive, not recruitingNCT04848337Phase 2Results postedReport a problem
- Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerActive, not recruitingNCT04781088Phase 2Results postedReport a problem
- Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017)CompletedNCT04776148Phase 3Results postedReport a problem
- Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61)CompletedNCT04704219Phase 2Results postedReport a problem
- Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)CompletedNCT04662710Phase 3Results postedReport a problem
- Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)CompletedNCT04428151Phase 2Results postedReport a problem
- Perioperative Lenvatinib With Pembrolizumab in Patients With Locally Advanced Nonmetastatic Clear Cell Renal Cell CarcinomaActive, not recruitingNCT04393350Phase 2Results postedReport a problem
- Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02)CompletedNCT04305041Phase 1/2Results postedReport a problem
- Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (The LENKYN Trial)TerminatedNCT04267120Phase 2Results postedReport a problem
- Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)TerminatedNCT04246177Phase 3Results postedReport a problem
- Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)CompletedNCT03976375Phase 3Results postedReport a problem
- Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001)CompletedNCT03884101Phase 3Results postedReport a problem
- Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)CompletedNCT03797326Phase 2Results postedReport a problem
- Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) for Advanced Melanoma in Anti-Programmed Death-1/Programmed Death-Ligand 1 (PD-1/L1)-Exposed Participants (MK-7902-004/E7080-G000-225/LEAP-004)CompletedNCT03776136Phase 2Results postedReport a problem
- Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid CancerTerminatedNCT03630120Phase 2Results postedReport a problem
- Lenvatinib and Pembrolizumab Simultaneous Combination StudyCompletedNCT03609359Phase 2Results postedReport a problem
- Lenvatinib and Eribulin in Advanced Soft Tissue SarcomaCompletedNCT03526679Phase 1/2Results postedReport a problem
- Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])CompletedNCT03517449Phase 3Results postedReport a problem
- A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)CompletedNCT03516981Phase 2Results postedReport a problem
- Study to Assess the Long-term Safety of Lenvatinib Monotherapy, a Lenvatinib Combination Regimen, or a Comparator Treatment Arm to Cancer Participants in Eisai Sponsored Lenvatinib TrialsCompletedNCT03477175Phase 2Results postedReport a problem
- A Study of Lenvatinib Plus Nivolumab in Participants With Hepatocellular CarcinomaCompletedNCT03418922Phase 1Results postedReport a problem
- A Phase II a Study of Lenvatinib, a Multi-targeted Tyrosine Kinase Inhibitor, Combined With Pembrolizumab (PD-1 Inhibitor) for the Treatment of Metastatic Gastroesophageal Cancer Patients Who Have Progressed on First or Subsequent Line TherapiesCompletedNCT03321630Phase 2Results postedReport a problem
- Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine TumorsCompletedNCT03290079Phase 2Results postedReport a problem
- A Trial of Lenvatinib Plus Pembrolizumab in Participants With Hepatocellular CarcinomaCompletedNCT03006926Phase 1Results postedReport a problem
- Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Participants With Selected Solid TumorsCompletedNCT03006887Phase 1Results postedReport a problem
- Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)CompletedNCT02973997Phase 2Results postedReport a problem
- A Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced DiseaseCompletedNCT02915783Phase 2Results postedReport a problem
- Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell CarcinomaActive, not recruitingNCT02811861Phase 3Results postedReport a problem
- Eribulin and Lenvatinib in Advanced Solid TumorsCompletedNCT02640508Phase 2Results postedReport a problem
- Study of Lenvatinib in Combination With Everolimus in Participants With Unresectable Advanced or Metastatic Renal Cell Carcinoma (RCC)CompletedNCT02454478Phase 1Results postedReport a problem
- A Study of E7050 in Combination With E7080 in Participants With Advanced Solid Tumors (Dose Escalation) and in Participants With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2)TerminatedNCT01433991Phase 1/2Results postedReport a problem
- Efficacy and Safety of HAIC Combined With Lenvatinib and PD-1 Inhibitors for Advanced Intrahepatic CholangiocarcinomaActive, not recruitingNCT07646717Phase 2Report a problem
- Efficacy and Safety Comparison Between PD-1 Inhibitor Combined With Lenvatinib or With Regorafenib For UHCC After Failure of First-line TreatmentCompletedNCT07537985Not applicableReport a problem
- Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular CarcinomaActive, not recruitingNCT07081633Phase 2Report a problem
- Study of Lenvatinib Plus Pembrolizumab in IO Refractory mRCC Patients With Brain MetastasesWithdrawnNCT07011849Phase 2Report a problem
- QL1706 Combined With Lenvatinib and GEMOX as First - Line Treatment for Unresectable Biliary Tract TumorsActive, not recruitingNCT06892925Phase 2Report a problem
- Neoadjuvant SBRT Combined With Lenvatinib and Pucotenlimab for Resectable Hepatocellular CarcinomaActive, not recruitingNCT06524466Phase 2Report a problem
- Second-line Treatment With CAdonilimab and LEnvatinib for Unresectable HCCWithdrawnNCT06361758Phase 2Report a problem
- A Study of Etoposide-carboplatin in Combination With Pembrolizumab and Lenvatinib Maintenance in HG-NETsActive, not recruitingNCT06232564Phase 2Report a problem
- Erlotinib in Combination With Select Tyrosine Kinase Inhibitors in Adult Patients With Advanced Solid TumorsWithdrawnNCT06161558Phase 1Report a problem
- Cadonilimab Combination With Lenvatinib as Neoadjuvant Therapy for ccRCCCompletedNCT06138496Phase 2Report a problem
- Perioperative TORIPALIMAB Plus LENVATINIB in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PLUTO)TerminatedNCT06114940Phase 2Report a problem
- A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast CancerActive, not recruitingNCT06110793Phase 1/2Report a problem
- AMG510 (sotorasib) Plus Lenvatinib As Second-line Treatment in Patients with KRASG12C Mutant, Metastatic NSCLCWithdrawnNCT06068153Phase 2Report a problem